ASHLEIGH HUFF: Open Payments
NPI 1306553888 · PETERSBURG, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$522 in 26 payments from 11 companies in 2025. Trend: 2023 $318 · 2024 $938 · 2025 $522
Food & beverage: $522
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $98 |
| AstraZeneca Pharmaceuticals LP | 5 | $98 |
| Lilly USA, LLC | 4 | $74 |
| Novo Nordisk Inc | 3 | $61 |
| ABBVIE INC. | 3 | $58 |
| GlaxoSmithKline, LLC. | 2 | $34 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $32 |
| Organon LLC | 1 | $20 |
| PFIZER INC. | 1 | $16 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $16 |
Products named: CAPLYTA, MOUNJARO, VRAYLAR, FARXIGA, BREZTRI, SHINGRIX, JARDIANCE, NEXPLANON.
Industry payments across VA — which companies pay providers there.
